[EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].

doi:MagyOnkol.2012.56.1.38

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

[EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].

Magyar onkologia - 1 Mar 2012

Moldvay Judit, Peták István

Abstract excerpt

Tailored therapy in lung cancer is one of the most exciting fields in translational research and also a nice example of fruitful collaboration between pulmonologists, clinical oncologists, pathologists and molecular biologists. This article, through a dialogue between a pathologist-clinician and a molecular biologist-pharmacologist, gives an overview about the most important questions on molecular targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung
Share to Carcinoma, Squamous Cell
Share to Drug Resistance, Neoplasm

Source

Open in PubMed

Identifiers

PMID: 22403761
DOI: MagyOnkol.2012.56.1.38

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interdisciplinary Communication

Share to Molecular Targeted Therapy

Share to Protein-Tyrosine Kinases

Share to Translational Research, Biomedical